VEGFA and ovarian hyperstimulation syndrome: A study on patients at high risk for OHSS has shown that oral administration of letrozole at doses of 2.5 mg, 5.0 mg, and 7.5 mg daily for five days post-oocyte retrieval significantly reduced serum estrogen and VEGF levels.